Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
postprandial hyperglycemia
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "postprandial hyperglycemia" in MCE Product Catalog:
4
Category:
Flavonoids Flavanols Metabolic Disease Phenols Polyphenols Plants Saxifragaceae Disease Research Fields
Target:
Synonyms: B28Asp; B28-Asp-insulin; INA-X 14; Insulin X 14
Target:
Research Areas:
Cat. No.: HY-W016993
CAS No.: 610-02-6
Category:
other families Ketones, Aldehydes, Acids Other Diseases Phenols Polyphenols Plants Disease Research Fields
Target:
Cat. No.: HY-W016993R
CAS No.: 610-02-6
Target:
Target:
Research Areas:
Glyparamide is an orally active hypoglycemic compound that serves as an auxiliary active ingredient in anti-diabetic agents. Glyparamide can be used in combination with preparations of Rhodamnia cinerea extract and is applicable to the study of hyperglycemia-related disorders-specifically those involving carbohydrate metabolism disturbances-including Type 2 diabetes, metabolic syndrome, and postprandial hyperglycemia. Other notable hypoglycemic agents of significant interest include: Tolbutamide (HY-B0401), Chlorpropamide (HY-B1429), Metformin (HY-B0627), and Glimepiride (HY-B0104) .
Cat. No.: HY-N11728
CAS No.: 1621988-60-0
Category:
Target:
Cat. No.: HY-163005
CAS No.: 3018963-27-1
Target:
Research Areas:
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
Cat. No.: HY-N17925
CAS No.: 1809429-26-2
Target:
Cat. No.: HY-182289
Target:
Research Areas:
LY-23 is an orally active α-glucosidase inhibitor (Ki = 0.05 μM), with IC50 values of 0.18 μM, 0.14 μM and 0.51 μM against maltase, sucrase and isomaltase, respectively. LY-23 reduces the level of postprandial blood glucose elevation. LY-23 is applicable to research related to postprandial hyperglycemia .
Cat. No.: HY-178383
Target:
Research Areas:
α-Glucosidase-IN-98 is a potent orally active α-Glucosidase inhibitor with an IC50 of 18.1 μM. α-Glucosidase-IN-98 reversibly binds with α-Glucosidase via hydrogen bonds, electrostatic interactions and hydrophobic effects, which induces significant conformational alterations in the secondary structure of α-Glucosidase. α-Glucosidase-IN-98 decreases postprandial hyperglycemia in Starch (HY-B2225B)/Sucrose (HY-B1779)-challenged mice. α-Glucosidase-IN-98 can be used for type 2 diabetes mellitus (T2DM) research .
Cat. No.: HY-19904B
CAS No.: 872260-19-0
Synonyms: (+)-LY2409021
Target:
Research Areas:
(+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
